	US 12,290,525 B2
	5 alpha dihydrotestosterone formulations and associated methods of use and treatment
Edward Dunne Corboy, Jr., Skokie, IL (US)
Appl. No. 18/702,485
Filed by Edward Dunne Corboy, Jr., Skokie, IL (US)
PCT Filed Dec. 5, 2023, PCT No. PCT/US2023/082601 § 371(c)(1), (2) Date Apr. 18, 2024, PCT Pub. No. WO2024/123833, PCT Pub. Date Jun. 13, 2024.
Claims priority of provisional application 63/430,320, filed on Dec. 5, 2022.
Prior Publication US 2024/0307410 A1, Sep. 19, 2024
Int. Cl. A61K 31/568 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 9/48 (2006.01); A61K 47/10 (2017.01); A61K 47/14 (2017.01); A61K 47/18 (2017.01); A61K 47/32 (2006.01)

CPC A61K 31/568 (2013.01) [A61K 9/0014 (2013.01); A61K 9/0053 (2013.01); A61K 9/06 (2013.01); A61K 9/48 (2013.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01); A61K 47/18 (2013.01); A61K 47/32 (2013.01)]

17 Claims

1. A method of supportive treatment in female to male transgender males with gender dysphoria receiving gender affirming hormone therapy comprising topically administering a composition or pharmaceutical formulation of 5 Alpha Dihydrotestosterone (5 Alpha-DHT), or a pharmaceutically acceptable salt or ester thereof, to the patient in an amount effective to promote hair growth; and

wherein the concentration of 5 Alpha-DHT in the composition or pharmaceutical formulation is selected from the group consisting of (i) ranges from about 0.00001% to about 50% weight to weight; (ii) ranges from 0.00001% to about 50%, weight to volume; and (iii) ranges from about 0.00001% to about 50%, volume to volume;

wherein the method promotes hair growth on the face, body, or pubic region of the patient; and

wherein the 5 Alpha-DHT composition or pharmaceutical formulation further comprises one or more dermal penetration enhancement agents that optimize hair follicle and hair shaft absorption when applied topically.